Navigation Links
JHP Pharmaceuticals Enters Agreement to Produce Unique Late Stage Ophthalmic Product
Date:9/16/2013

PARSIPPANY, N.J., Sept. 16, 2013 /PRNewswire/ -- JHP Pharmaceuticals, a leading provider of global contract manufacturing services for sterile products, is pleased to announce that it has entered into a manufacturing agreement with an undisclosed pharmaceutical company which has developed proprietary products that provide sustained and localized drug concentration. The agreement is for technical transfer, registration batch manufacture and commercial supply of a unique late stage ophthalmic product.

JHP's manufacturing expertise and cGMP compliance history were critical factors in the selection process. Stuart Hinchen, President and CEO stated, "This important product has critical manufacturing requirements. We have successfully manufactured and filled a number of different products over the past few years, all with unique parameters. Our experience in this area provides our customers with a sound resource as the product moves through launch and commercialization. Our record of cGMP compliance driven by experienced quality and regulatory teams continues to be one of the key reasons customers chose JHP." 

Hinchen noted, "JHP is now expanding its manufacturing capabilities by introducing a new ophthalmic filling line that will further enhance production effectiveness. This innovative equipment will offer a disposable filling circuit, reduced line losses and broader product handling capabilities all in a restricted access configuration. At the moment, the new filling line is under construction and is expected to be fully operational during the second half of 2014."

JHP Pharmaceuticals, located in Rochester, Michigan, has over 27 years' experience in contract manufacturing. It has developed many partnerships in its history manufacturing clinical and commercial products. JHP has successfully supported launches of several products in US and international markets. Currently it manufactures products for sale in 86 countries. 

About JHP Pharmaceuticals, LLCJHP Pharmaceuticals, headquartered in New Jersey, provides contract manufacturing of sterile products including biologics, small molecule, controlled substances, vaccines, ophthalmics, otics and antibiotics for large and small pharmaceutical and biotech organizations.

JHP's sterile manufacturing facility, located in Rochester Michigan sits on over 85 acres of land and includes a 171,000 sq. ft. production building and warehouse.  The production facility utilizes three high-speed filling lines, a clinical filling line, an ophthalmic filling line and four lyophilizers.  The site includes a new, innovatively-designed facility for chemistry, sterility testing and analytical methods development. 

JHP has the capability to manufacture small-scale clinical through large-scale commercial products.  JHP employs more than 400 staff in the USA in its manufacturing, product development, regulatory, sales and marketing and corporate areas.  For more information, please visit www.jhppharma.com.Contact:Dan Leone 973.658.3559Bill Conway  877.906.7556 jhpcontractservices@jhppharma.com MK513 


'/>"/>
SOURCE JHP Pharmaceuticals
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Actinium Pharmaceuticals Appoints Kaushik J. Dave, Ph.D., MBA As President, Chief Executive Officer And Director
2. Frost & Sullivan Lauds Adcock Ingrams Capability to Innovatively Cater to the Dynamic Needs of Emerging Pharmaceuticals Markets
3. Dr. David Hangauer, Chief Scientific Officer and Co-Founder, commits his career to Kinex Pharmaceuticals
4. Access Pharmaceuticals Awarded Second European Patent for MuGard
5. Cardioxyl Pharmaceuticals Appoints Shi Yin Foo, M.D., Ph.D., As Chief Medical Officer
6. Caldera Pharmaceuticals Announces Closing of Financing
7. HedgePath Pharmaceuticals Enters into Key Collaboration with Mayne Pharma
8. Boehringer Ingelheim Expands Investigation of Interferon-free Hepatitis C Treatment Regimens to Reach More Patient Types through Presidio Pharmaceuticals Clinical Collaboration
9. Roche and Inovio Pharmaceuticals partner on Inovios prostate cancer and hepatitis B immunotherapy products
10. UHC to Launch New Specialty Pharmacy Program for Better Continuity of Patient Care, Improved Access to Specialty Pharmaceuticals
11. DelMar Pharmaceuticals and Guangxi Wuzhou Pharmaceuticals Establish Clinical Advisory Board in China
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... April 20, 2017 NeuroVive Pharmaceutical AB ... announced positive preclinical results demonstrating anti-fibrotic effects ... non-alcoholic steatohepatitis (NASH), in an additional well-validated ... NV556 has previously shown similar anti-fibrotic effects ... NeuroVive,s scientists present novel data demonstrating anti-fibrotic ...
(Date:4/19/2017)... Calif. , April 19, 2017  IRIDEX Corporation ... will release financial results for the first quarter 2017 ... 2017.  The Company,s management team will host a corresponding ... p.m. ET. Investors interested in listening to ... 707-0665 for domestic callers or (703) 326-3030 for international ...
(Date:4/19/2017)... April 19, 2017  Sorrento Therapeutics, Inc. (NASDAQ: ... biopharmaceutical company developing new treatments for cancer and ... of its previously announced underwritten public offering of ... public offering price of $2.00 per share, before ... expenses payable by Sorrento.  The net proceeds to ...
Breaking Medicine Technology:
(Date:4/24/2017)... , ... April 24, 2017 , ... Come to PAINWeekEnd ... 4200 Jim Walter Blvd, for an educational and exciting 2-day program. , An ... staff hearing this before they approach patients” about the course entitled Ain't Misbehavin': Decreasing ...
(Date:4/24/2017)... ... April 24, 2017 , ... Donna Parker, L. Ac. reads ... not found any of them to be very practical. She wanted to write a ... make changes in their health. It prompted her in writing “ A Clear Path ...
(Date:4/24/2017)... ... , ... “Reflections of God’s Work”: an enlightening collection of life lessons leading ... of published author, Jerri Broglin, a survivor of great loss who gained insight on ... eye-opener for those searching for answers, as we are finding the answers that are ...
(Date:4/24/2017)... , ... April 24, 2017 , ... “The Saint with ... with Trin, and Omega Station” is the creation of published author, Chris Jackson. ... Metroplex where he works in the Dallas Independent School District teaching English. He is ...
(Date:4/24/2017)... (PRWEB) , ... April 24, 2017 , ... Life of ... University of Florida. The event will be held at 7:30 pm on May 10th ... Block and Drew Copeland of Sister Hazel, will support the UF Collegiate Recovery Community ...
Breaking Medicine News(10 mins):